Sun, Jul 13, 2014, 6:12 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

TaxuCardium Pharmaceuticals Group Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • dctrme dctrme Oct 8, 2009 6:36 PM Flag

    CXM holders

    generx will evolve, but possibly with different delivery method.Generx is still many years away.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • custompcmodz Oct 8, 2009 7:29 PM Flag

      Stop messing around and check this out.!!!

      Another Trusted pick brought to by Toonicestocks( A Google Group) .

      With roughly 47 Million O/S, we are going to see CXM jump up huge when they announce their Data From Matrix Excellarate Phase 2B Clinical Study For Wound Repair And Regeneration. THIS IS NOT AN OTC, THIS IS AMEX AND MMs will know once I just revealed this hidden gem, they will jump on board too.

      Positive results we will RETEST the 52 week high of $3.12, however with data meeting all endpoints and showing great efficiency, I see this soaring even pass the 52 week high and easily going more than 100%-150%

      IN THERE RECENT 8-K FILING ON OCT. 5TH, they state that "On October 1, 2009, Cardium Therapeutics, Inc. (“Cardium”) issued a press release announcing that it plans to report on preliminary safety and efficacy data from its Matrix Phase 2b Excellarate clinical study on or before October 14, 2009 and the acceptance of the Phase 1/2 clinical study for publication in Wound Repair and Regeneration. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein"

      All indications seem to make their results for Phase 2 seem very promising and very positive. I am extremely BULLISH on CXM results. Please view link below and research package i have put together.

0.5802-0.0098(-1.66%)Jul 11 2:34 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.